Soligenix Q3 2026: Cash Up to $9.0M, Net Loss Narrows, Going Concern Persists
SNGX sits 20% above its 52-week low of $0.28.
Summary
Soligenix reported $9.02 million in cash at September 30, 2026 and a narrower $5.93 million nine-month loss, funded largely by 13.27 million ATM shares sold at a $0.52 average. Going-concern doubt remains, and the Nasdaq bid-price cure deadline is December 7, 2026.
Key Events · Earnings and Guidance · SNGX
-
Q3 Cash Rises to $9.0M on ATM Sales
Cash and cash equivalents were $9,023,510 at September 30, 2026 versus $7,936,153 at December 31, 2025, a $1,087,357 increase driven by ATM proceeds.
-
13.27M ATM Shares Sold at $0.52 Average
The company sold 13,269,936 shares under the Rodman Sales Agreement for gross proceeds of $6,901,000 and net proceeds of $6,682,000; shares outstanding rose from 10,086,130 to 23,368,754. About $1.8 million of ATM capacity remains.
-
Nine-Month Loss Narrows to $5.93M
Net loss was $5,929,844 versus $8,184,191 a year earlier, as R&D fell to $3,113,403 from $5,202,573 after the June 2026 HyBryte termination.
-
Going Concern Doubt Still Disclosed
Management cites runway into the second quarter of 2028 but states substantial doubt about continuing as a going concern absent new capital or a strategic transaction; accumulated deficit is $250,980,976.
Analysis · SNGX · Life Sciences
Cash stood at $9.02 million at the end of September, up from $7.94 million at year-end, after Soligenix sold 13.27 million shares through its Rodman ATM at a weighted average of $0.52 for $6.90 million gross. That cash buys time—management projects runway into the second quarter of 2028—but the company still carries a $250.98 million accumulated deficit and explicitly states substantial doubt about its ability to continue as a going concern, because no strategic transaction has been signed. The nine-month net loss narrowed to $5.93 million from $8.18 million, mostly because the failed HyBryte program was terminated in June 2026 and R&D spending fell to $3.11 million from $5.20 million. The offsetting cost is dilution: shares outstanding went from 10,086,130 to 23,368,754, and only about $1.8 million of ATM capacity remains. Nasdaq's $1.00 minimum bid deadline is December 7, 2026, and the stock at $0.335 is far below it; stockholders have already authorized a reverse split of 1-for-2 to 1-for-20 if the board chooses to use it.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNGX was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.3M. The 52-week trading range was $0.28 to $1.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.